istaroxime + digoxin

Istaroxime + digoxin is a combination of two cardiotonic drugs. **Istaroxime** is a novel intravenous inotropic and lusitropic agent under investigation for acute heart failure, acting through dual mechanisms: it inhibits the Na^+/K^+ adenosine triphosphatase (ATPase), like digoxin, leading to increased intracellular calcium and enhanced cardiac contractility, and it selectively stimulates the sarco/endoplasmic reticulum Ca^2+ ATPase isoform 2 (SERCA2a), promoting improved cardiac relaxation[1][2]. **Digoxin** is a well-established cardiac glycoside that primarily inhibits the Na^+/K^+ ATPase, increasing intracellular calcium and improving contractility, though with less selectivity for SERCA2a and greater risk of proarrhythmic activity[1][2]. Together, this combination could theoretically offer complementary and potentially synergistic effects in acute heart failure, but clinical studies have traditionally excluded their concomitant use due to risk of additive toxicity and arrhythmia[1].

Other names

istaroxime + digoxin